Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.

Find People
Find Research
Overview
Tutorials
FAQs
Edit My PROFILE
Login to PROFILES

Contact Us
If you have any questions or feedback please contact us.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.

Adams S, Diamond JR, Hamilton E, Pohlmann PR, Tolaney SM, Chang CW, Zhang W, Iizuka K, Foster PG, Molinero L, Funke R, Powderly J. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial. JAMA Oncol. 2019 03 01; 5(3):334-342.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Albumins
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Disease Progression
Female
Humans
Middle Aged
Neoplasm Metastasis
Neoplasm Recurrence, Local
Neoplasm Staging
Paclitaxel
Time Factors
Triple Negative Breast Neoplasms
United States

authors with profiles

Jennifer R Diamond

Contact Us
CCTSI
About CCTSI
CCTSI Affiliated Institutions
National CTSA Consortium